Nano-encapsulation of coenzyme Q10 in secondary and tertiary nano-emulsions for enhanced cardioprotection and hepatoprotection in human cardiomyocytes and …
V Quagliariello, R Vecchione, A De Capua… - International Journal …, 2020 - Taylor & Francis
Introduction CoenzymeQ10 (CoQ10) is a well-known antioxidant and anti-inflammatory
agent with cardioprotective properties. However, clinical trials based on its oral …
agent with cardioprotective properties. However, clinical trials based on its oral …
Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine
In this chapter, we will review the nanomedicines which are already available on the market,
those that are currently in clinical trials, and the nanoformulations at the preclinical …
those that are currently in clinical trials, and the nanoformulations at the preclinical …
Impact of prior (neo) adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer
Y Kanjanapan, SW Lok, P Gibbs, R De Boer… - Breast cancer research …, 2020 - Springer
Purpose Trastuzumab, pertuzumab, and docetaxel are the standard first-line therapy for
HER2-positive (HER2+) metastatic breast cancer (MBC). However, only 10% of patients …
HER2-positive (HER2+) metastatic breast cancer (MBC). However, only 10% of patients …
[HTML][HTML] Expression of angiopoietin-like 4 fibrinogen-like domain (cANGPTL4) increases risk of brain metastases in women with breast cancer
Background: Brain metastases challenge daily clinical practice, and the mechanisms by
which cancer cells cross the blood-brain barrier remain largely undeciphered. Angiopoietin …
which cancer cells cross the blood-brain barrier remain largely undeciphered. Angiopoietin …
Epidemiology and socioeconomic impact of CNS metastases
JA Wilcox, LM DeAngelis - Central Nervous System Metastases: Diagnosis …, 2020 - Springer
Brain metastases are the most common tumor of the central nervous system with an overall
incidence ranging from 8% to 26%. The most common malignancies to metastasize to the …
incidence ranging from 8% to 26%. The most common malignancies to metastasize to the …
Cardiotoxicity of trastuzumab and other HER2-targeted agents
JP Morgan, D Hayes, S Vora - UpToDate (eds. Hayes, DF and Vora …, 2020 - uptodate.com
Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor
receptor 2 (HER2, also called ErbB2). For the 15 to 20 percent of patients with breast cancer …
receptor 2 (HER2, also called ErbB2). For the 15 to 20 percent of patients with breast cancer …
[PDF][PDF] Neuro-Oncology Advances
HY Cho, S Swenson, TZ Thein, W Wang, NR Wijeratne… - 2020 - pdfs.semanticscholar.org
Background. Breast cancer is the second most common cancer associated with brain
metastases. The purpose of this study was to identify factors that impact the time to brain …
metastases. The purpose of this study was to identify factors that impact the time to brain …